Literature DB >> 753456

The role of bone scanning in the assessment of prostatic carcinoma.

B McGregor, A G Tulloch, M F Quinlan, F Lovegrove.   

Abstract

Fifty new cases of carcinoma of the prostate were assessed prior to treatment to determine the incidence of bony metastases. The radioisotope bone scan was the most sensitive method of detecting metastases and of localising them. It was twice as accurate as the serum acid phosphatase estimation. Skeletal X-rays were the least accurate method. Forty-six per cent of patients had abnormal bone scans at presentation. The histological grade of the tumour correlated well with the bone scan. The higher the grade, the more likely was the bone scan to be abnormal. There is need for greater accuracy in detecting metastases, and the bone marrow acid phosphatase estimation, either alone or in conjunction with the bone scan, may provide this accuracy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 753456     DOI: 10.1111/j.1464-410x.1978.tb02798.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  8 in total

1.  [Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis].

Authors:  T Klatte; D Klatte; M Böhm; E P Allhoff
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

2.  The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.

Authors:  S Ataus; A Citçi; B Alici; A U Onder; K Sönmezoğlu; A Erözenci; V Solok
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

3.  Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer.

Authors:  Vidija Soerdjbalie-Maikoe; Rob C M Pelger; Guus A B Lycklama à Nijeholt; Jan-Willem Arndt; Aeilko H Zwinderman; Herman Bril; Socrates E Papapoulos; Neveen A T Hamdy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-19       Impact factor: 9.236

4.  99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer.

Authors:  Maurits Wondergem; Friso M van der Zant; Remco J J Knol; Anne Marij G Burgers; Siebe D Bos; Igle J de Jong; Jan Pruim
Journal:  World J Urol       Date:  2017-10-17       Impact factor: 4.226

5.  When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.

Authors:  Yiwei Lin; Qiqi Mao; Bin Chen; Liujiang Wang; Ben Liu; Xiangyi Zheng; Liping Xie
Journal:  BMC Urol       Date:  2017-06-12       Impact factor: 2.264

6.  Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy.

Authors:  Koramadai Karuppusamy Kamaleshwaran; Bhagwant Rai Mittal; Chidambaram Natrajan Balasubramanian Harisankar; Anish Bhattacharya; Shrawan Kumar Singh; Arup K Mandal
Journal:  Indian J Nucl Med       Date:  2012-04

7.  Bone scan is of doubtful value as a first staging test in the primary presentation of prostate cancer.

Authors:  Lina M Carmona Echeverria; Lawrence Drudge-Coates; C Jason Wilkins; Gordon H Muir
Journal:  ISRN Oncol       Date:  2012-11-05

8.  EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study.

Authors:  Anna K Campos; Hilde D Hoving; Stefano Rosati; Geert J L H van Leenders; Igle J de Jong
Journal:  Int J Mol Sci       Date:  2016-09-29       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.